Thesis

  1. Posibles alteraciones en la relación farmacocinética-farmacodinámica de la metadona durante un síndrome de abstinencia espontáneo 1997

    Universidad del País Vasco - Euskal Herriko Unibertsitatea

Supervised Theses (5)

  1. Design and in vitro/in vivo evaluation of a targeted immunotherapy platform for the treatment of melanoma 2018

    Universidad de Navarra

    Merino Díaz, María

  2. Development of an in-vivo platform to evaluate the PK-PD relationship of an anti-PD-L1 mAb in a syngeneic mouse model of melanoma 2017

    Universidad de Navarra

    Contreras Sandoval, Ana Margarita

  3. Design and in-vitro/in-vivo evaluation in colon cancer cells of targeted oxaliplatin liposomes to epidermal growth factor receptor by conjugation of different ligands 2013

    Universidad de Navarra

    Zalba Oteiza, Sara

  4. Desarrollo y evaluación cinético-dinámica de sistemas poliméricos para la vehiculización de cisplatino 2009

    Universidad de Navarra

    Moreno Luqui, Daniel

  5. Aplicacion de los modelos pk/pd en ensayos pre clinicos y clinicos en analgesia 2006

    Universidad de Navarra

    SAYAR BERISTAIN, ONINTZA

Theses Committees (14)

  1. Secretary of the Committee

    Gene therapy and mRNA strategies to improve cytokine-based immunotherapy 2021

    Universidad de Navarra

    Fernández Fernández, Myriam

  2. Chair of the Committee

    Development of disease and drug models for rare diseases: Application to Acute Intermittent Porphyria 2021

    Universidad de Navarra

    Vera-Yunca, D.

  3. Chair of the Committee

    Systems pharmacology in modelling complex scenarios: Opportunities and challenges 2019

    Universidad de Navarra

    Ruiz Cerdá, María Leire

  4. Secretary of the Committee

    Pharmacokinetic/Pharmacodynamic Modelling-Based Translational Approach applied to the Anticancer Drug Gemcitabine in Advanced Pancreatic and Ovarian Cancer 2017

    Universidad de Navarra

    García-Cremades Mira, María

  5. Secretary of the Committee

    Pharmacokinetic/pharmacodynamic modelling during development of novel drugs for the treatment of sleep disorders 2013

    Universidad de Navarra

    Madrid Aispuro, Arianna

  6. Secretary of the Committee

    Pharmacokinetic-pharmacodynamic modelling of therapeutic proteins 2013

    Universidad de Navarra

    Parra Guillén, Zinnia Patricia

  7. Committee Member

    Nanostructured lipid carriers as vehicles for the delivery of poorly water-soluble drugs 2013

    Universidad del País Vasco - Euskal Herriko Unibertsitatea

    Beloqui García, Ana

  8. Secretary of the Committee

    New chemotherapy approaches based on mucus-penetrating nanoparticles as carriers for paclitaxel 2012

    Universidad de Navarra

    Calleja, Patricia

  9. Committee Member

    Estudio farmacocinético preclínico de un inhibidor de la sulfatasa esteroidal 2012

    Universitat de Barcelona

    Blanch López, Silvia Elisabet

  10. Secretary of the Committee

    Semi-mechanistic modelling of neutropenia in oncology drug development 2010

    Universidad de Navarra

    Soto Rodríguez, María Elena

  11. Committee Member

    Farmacocinética y farmacodinamia del bromuro de rocuronio: Influencia de la terapia crónica con fenitoína. 2010

    Universitat de Barcelona

    Fernández Candil, Juan Luis

  12. Secretary of the Committee

    Semi-mchanistic pk/pd modelling in oncology drug development 2007

    Universidad de Navarra

    BUENO BURGOS, LOREA

  13. Secretary of the Committee

    Modelización farmacocinetica/farmacodinamica de respuestas no-continuas 2002

    Universidad de Navarra

    RAPADO SANTAOLALLA, JAVIER

  14. Secretary of the Committee

    Descripción mediante modelos farmacocinéticos/farmacodinámicos del efecto antipirético y antiinflamatorio del naproxeno en rata 2000

    Universidad de Navarra

    JOSA ALBIÑANA, MARIONA